Research programme: tetrapeptide kappa-opioid receptor agonist- MUSC Foundation for Research Development/Titan Pharmaceuticals
Latest Information Update: 27 Oct 2021
At a glance
- Originator Titan Pharmaceuticals
- Class Antipruritics; Opioid peptides; Skin disorder therapies
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Pruritus
Most Recent Events
- 12 Oct 2021 Titan Pharmaceuticals and MUSC Foundation Research Development agree to co-promote [and co-develop]tetrapeptide kappa-opioid receptor agonist
- 12 Oct 2021 MUSC Foundation Research Development has patent protection for tetrapeptide kappa-opioid receptor agonists in USA, prior to October 2021
- 12 Oct 2021 Early research in Pruritus in USA (Parenteral)